Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children.
Saraban K, Suntarattiwong P, Chantasrisawad N, Boonsathorn S, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaruampornpan P, Srisarang S, Puthanakit T; KIDSVAX study team. Saraban K, et al. Among authors: tangsathapornpong a. Vaccine X. 2023 Nov 24;15:100414. doi: 10.1016/j.jvacx.2023.100414. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38090644 Free PMC article.
Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases.
Chantasrisawad N, Puthanakit T, Tangsathapornpong A, Techasaensiri C, Phongsamart W, Suwanpakdee D, Jaruampornpan P, Sophonphan J, Suntarattiwong P, Chotpitayasunondh T; Study Team. Chantasrisawad N, et al. Among authors: tangsathapornpong a. Vaccines (Basel). 2022 May 29;10(6):871. doi: 10.3390/vaccines10060871. Vaccines (Basel). 2022. PMID: 35746478 Free PMC article.
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
Chantasrisawad N, Puthanakit T, Kornsitthikul K, Jaru-Ampornpan P, Tawan M, Matapituk P, Sophonphan J, Anugulruengkitt S, Tangsathapornpong A, Katanyutanon A; KIDSBOOST study team*. Chantasrisawad N, et al. Among authors: tangsathapornpong a. Vaccine X. 2022 Sep 30;12:100221. doi: 10.1016/j.jvacx.2022.100221. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36213592 Free PMC article.
The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
Chantasrisawad N, Techasaensiri C, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaru-Ampornpan P, Sophonphan J, Suntarattiwong P, Puthanakit T; KIDSVAX study team. Chantasrisawad N, et al. Among authors: tangsathapornpong a. Int J Infect Dis. 2023 May;130:52-59. doi: 10.1016/j.ijid.2023.02.017. Epub 2023 Feb 24. Int J Infect Dis. 2023. PMID: 36841501 Free PMC article. Clinical Trial.
Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand.
Chotpitayasunondh T, Pruekprasert P, Puthanakit T, Pancharoen C, Tangsathapornpong A, Oberdorfer P, Kosalaraksa P, Prommalikit O, Tangkittithaworn S, Kerdpanich P, Techasaensiri C, Korejwo J, Chuenkitmongkol S, Houillon G. Chotpitayasunondh T, et al. Among authors: tangsathapornpong a. Vaccine. 2017 Jan 5;35(2):299-304. doi: 10.1016/j.vaccine.2016.11.062. Epub 2016 Nov 28. Vaccine. 2017. PMID: 27903416 Free article. Clinical Trial.
Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
Choi UY, Kim KH, Lee J, Eun BW, Kim DH, Ma SH, Kim CS, Lapphra K, Tangsathapornpong A, Kosalaraksa P, Oberdorfer P, Kim HM, Shin SM, Kang JH. Choi UY, et al. Among authors: tangsathapornpong a. Vaccine. 2021 Mar 19;39(12):1758-1764. doi: 10.1016/j.vaccine.2021.02.013. Epub 2021 Feb 21. Vaccine. 2021. PMID: 33627245 Clinical Trial.
High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, Srimuan P, Kowitdamrong E, Savangsindh P, Sophonphan J, Tantawichien T, Tangsathapornpong A. Angsuwatcharakon P, et al. Among authors: tangsathapornpong a. Vaccine. 2021 Oct 8;39(42):6206-6209. doi: 10.1016/j.vaccine.2021.08.079. Epub 2021 Sep 21. Vaccine. 2021. PMID: 34556367 Clinical Trial.
Seroprevalence of mumps among children and adolescents in Thailand, 2020.
Anugulruengkitt S, Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, Srimuan P, Kowitdamrong E, Sawangsinth P, Sophonphan J, Tantawichien T, Tangsathapornpong A. Anugulruengkitt S, et al. Among authors: tangsathapornpong a. Vaccine. 2022 Feb 16;40(8):1061-1064. doi: 10.1016/j.vaccine.2022.01.019. Epub 2022 Jan 22. Vaccine. 2022. PMID: 35078667
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, Sodsai P, Himananto O, Sophonphan J, Suchartlikitwong P, Hiransuthikul N, Angkasekwinai P, Tangsathapornpong A, Hirankarn N; study team. Nanthapisal S, et al. Among authors: tangsathapornpong a. Vaccine. 2022 Apr 20;40(18):2551-2560. doi: 10.1016/j.vaccine.2022.03.036. Epub 2022 Mar 24. Vaccine. 2022. PMID: 35341647 Free PMC article. Clinical Trial.
Low Measles Seropositivity Rate among Thai Adolescents in the Thai National Immunization Program.
Puthanakit T, Anugulruengkitt S, Angsuwatcharakon P, Bunjoungmanee P, Kowitdamrong E, Primsirikunawut A, Intarakhao S, Chetsonwisorn P, Sophonphan J, Tangsathapornpong A. Puthanakit T, et al. Among authors: tangsathapornpong a. Vaccines (Basel). 2022 Aug 6;10(8):1269. doi: 10.3390/vaccines10081269. Vaccines (Basel). 2022. PMID: 36016157 Free PMC article.
31 results